Recent Headlines
The "Monoclonal Antibodies (mAbs) Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. (full story)
Spindletop Capital Management, a healthcare-focused growth equity firm, is pleased to announce the promotion of Kelly Huang, Ph.D. as a Managing Director of Spindletop Capital. The promotion was in recognition of Dr. Huang's role (full story)
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:00 a.m. (Eastern Time) on Wednesday, January 22nd to review fourth-quarter results. Alex Gorsky, Chairman and Chief Executive Officer; Joseph J. Wolk, Ex (full story)
JNJ: 140.98 (+0.99)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing that the addition of Darzalex(R) (daratumumab) to carfilzomib (Kyprolis(R)) and dexamethasone (DKd), compared (full story)
JNJ: 140.98 (+0.99)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 3 CANDOR study showing the addition of DARZALEX® (daratumumab) to carfilzomib (Kyprolis®) and dexamethasone (DKd), compared t (full story)
JNJ: 140.98 (+0.99)
Performance Comparison
| Name | Today | 3-Month | 1-Year |
| JNJ |
 +0.71% |
 +8.45% |
 -3.77% |
Growth Rates
| YTD | +9.24% | |||
| 1-Year | +5.26% | |||
| 3-Year | +20.81% | |||
| 5-Year | +32.63% | |||
| 10-Year | +117.34% |